Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance

PSC‐833 reverses multidrug resistance by P‐glycoprotein at concentrations <1000 ng/ml. A phase I study of PSC‐833 and doxorubicin was conducted to determine the maximum tolerated dose and to investigate pharmacokinetics. PSC‐833 was intravenously infused as a 2‐h loading dose (LD) and a subsequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Minami, Hironobu, Ohtsu, Tomoko, Fujii, Hirofumi, Igarashi, Tadahiko, Itoh, Kuniaki, Uchiyama‐Kokubu, Noriko, Aizawa, Tetsushi, Watanabe, Torn, Uda, Yoshinori, Tanigawara, Yusuke, Sasaki, Yasutsuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2001
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926698/
https://www.ncbi.nlm.nih.gov/pubmed/11223552
http://dx.doi.org/10.1111/j.1349-7006.2001.tb01085.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926698/
https://www.ncbi.nlm.nih.gov/pubmed/11223552
http://dx.doi.org/10.1111/j.1349-7006.2001.tb01085.x

Ejemplares similares